Diagnostic & targeting reagents for lung cancer

诊断

• 批准号: 6983025
• 负责人: Kathlynn C Brown
• 金额: $ 36.32万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-07 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6983025
• 关键词: SCID mouse; athymic mouse; biomarker; cell line; cell surface receptors; chemical binding; clinical research; diagnosis design /evaluation; drug delivery systems; human tissue; lung neoplasms; neoplasm /cancer diagnosis; peptides; phage display; receptor binding

DESCRIPTION (provided by applicant): Lung cancer is the largest cancer killer of both men and women in the United States. Discovery of ligands specific to receptor(s) on a surface of a lung cancer cell will impact clinical issues including functional diagnosis and cell-specific drug delivery. Our overall goal is to generate a panel of cell specific molecules that could be used to classify tumor types and then be exploited for targeted delivery of therapeutics. Using phage display technologies, my laboratory has developed platform methodologies to isolate peptides that bind to and mediate uptake into specific cells. We have successfully identified cell-specific targeting peptides for 30 different cell types, including 7 cancer cell lines. The isolated peptides display remarkable cell-specificities, even among similar cells, and are able to discriminate between normal and cancerous cells as well as different lung tumor cells. This high discriminating power suggests that peptides could be identified that selectively bind to different tumor types, even those with similar classifications. We propose to isolate cell-targeting peptides for 16 different lung cancer lines and then utilize these peptides as diagnostic and tumor specific delivery reagents. These peptides will be assayed for affinity and cell-specificity. Efforts will be directed towards translating the targeting phage into small molecule targeting reagents and these peptide scaffolds will be utilized to deliver therapeutics to tumor cells both in vitro and in vivo. The cell specificity demonstrated by these peptides indicates that they are recognizing distinct cell surface receptors that may be of clinical value as biomarkers for lung cancer. Thus, we will utilize the peptides to identify the cellular these unique cellular features. We will then explore the expression patterns of the receptor on a panel of human lung cancer tissues by immunohistochemistry and compare this with the expression level in matched normal tissues. Achieving our goals will impact lung cancer diagnosis and treatment as well as solving general challenges in the field of targeted drug delivery.

描述（由申请人提供）：肺癌是美国男性和女性最大的癌症杀手。肺癌细胞表面特异性受体配体的发现将影响包括功能诊断和细胞特异性药物递送在内的临床问题。我们的总体目标是生成一组细胞特异性分子，可用于对肿瘤类型进行分类，然后用于靶向递送治疗。利用噬菌体展示技术，我的实验室开发了平台方法来分离与特定细胞结合并介导摄取的肽。我们已经成功地鉴定了30种不同细胞类型的细胞特异性靶向肽，包括7种癌细胞系。分离的肽显示出显著的细胞特异性，甚至在相似的细胞中，并且能够区分正常细胞和癌细胞以及不同的肺肿瘤细胞。这种高分辨能力表明，可以识别出选择性结合不同肿瘤类型的肽，甚至是那些分类相似的肿瘤。我们拟分离出16种不同肺癌细胞系的细胞靶向肽，然后将这些肽用作诊断和肿瘤特异性递送试剂。这些肽将被检测亲和力和细胞特异性。研究人员将努力将靶向噬菌体转化为小分子靶向试剂，并利用这些肽支架在体外和体内向肿瘤细胞输送治疗药物。这些肽所显示的细胞特异性表明，它们可以识别不同的细胞表面受体，这些受体可能作为肺癌的生物标志物具有临床价值。因此，我们将利用肽来识别细胞这些独特的细胞特征。然后，我们将通过免疫组织化学方法探索该受体在人类肺癌组织中的表达模式，并将其与匹配的正常组织中的表达水平进行比较。实现我们的目标将影响肺癌的诊断和治疗，以及解决靶向给药领域的一般挑战。